Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

InterCure Ltd. (INCR) vs Incannex Healthcare Inc. (IXHL)

InterCure Ltd. and Incannex Healthcare Inc. are both Drug Manufacturers Specialty & Generic companies. InterCure Ltd. is the larger, with a market value of $62.3M against $40.7M — 1.5× the size. Incannex Healthcare Inc. has negative trailing earnings, so its P/E is not meaningful; InterCure Ltd. trades at 9.8×. InterCure Ltd. has the higher net margin (4.88% vs 0.00%) and the higher return on invested capital (0.00% vs −2,022.1%). Across the 16 metrics below, InterCure Ltd. leads on 11 and Incannex Healthcare Inc. on 5.

Valuation

Metric INCR IXHL Drug Manufacturers Specialty & Generic median
P/E 9.84 n/m 20.14
P/S 1.98 26.27 2.25
P/B 1.96 0.54 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 23.47 1.18 12.29
EV/Sales 2.12 (19.01) 2.56
Earnings yield 10.16% (514.59%) (2.99%)
Free cash flow yield (0.34%) (43.26%) 0.00%

Profitability

Metric INCR IXHL Drug Manufacturers Specialty & Generic median
Gross margin 32.74% (0.10%) 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 4.88% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (117.17%) (0.40%)
Return on assets 0.00% (100.36%) (3.32%)
Return on invested capital 0.00% (2,022.08%) 0.00%

Growth

Metric INCR IXHL Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 16.15% — 10.01%
EPS growth (last fiscal year) 52.50% (17.39%) —
Revenue growth, 5-year CAGR 31.11% (29.64%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INCR IXHL Drug Manufacturers Specialty & Generic median
Debt to equity 0.27 0.00 0.05
Current ratio 1.85 41.56 2.31
Net debt to EBITDA (4.07) 0.64 0.85

Dividend

Metric INCR IXHL Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric INCR IXHL Drug Manufacturers Specialty & Generic median
Market cap 62.33m 40.66m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack